Clinical Research Directory

Inclusion Criteria for patients: Patients with von Willebrand disease (VWD) or acquired von Willebrand syndrome (AVWS) Age ≥ 16 years. Previous diagnosis of von Willebrand disease or acquired von Willebrand syndrome, defined as one of the following: Group A - Type 1 VWD: VWF levels ≤ 30 IU/dL, regardless of bleeding history, or VWF levels ≤ 0.50 IU/mL in the presence of abnormal bleeding. Group B - Congenital or acquired VWD (VWD or AVWS): Diagnosis of congenital or acquired VWD, with or without gastrointestinal bleeding. Group C - Subgroup study (Type 2A VWD): One patient with type 2A VWD selected for a dedicated sub-study involving allele-specific siRNA silencing of the mutant allele. Ability and willingness to provide written informed consent. For patients without prior molecular characterization: willingness to undergo VWF gene sequencing and to sign the related informed consent. Inclusion criteria for healthy volunteers * No prior diagnosis of VWD, bleeding disorders, or thrombotic disorders. * Willingness to donate blood for study procedures. * Ability and willingness to provide written informed consent. * Age ≥ 18 years. Exclusion criteria for both patients and healthy volunteers: * Pregnancy. * Anemia, as determined at screening or based on medical history.